Document Detail

Comparison of two doses of recombinant human bone morphogenetic protein in absorbable collagen sponges for bone healing in dogs.
MedLine Citation:
PMID:  17669023     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To determine the effects of 2 doses of recombinant human bone morphogenetic protein-2 in an absorbable collagen sponge (rhBMP-2/ACS) on bone healing in dogs. ANIMALS: 27 adult dogs. PROCEDURES: Dogs underwent a mid-diaphyseal (1-mm) tibial osteotomy (stabilized with external skeletal fixation) and received an ACS containing 0.28 mg (0.2 mg/mL) or 0.56 mg (0.4 mg/mL) of rhBMP-2 or no treatment (control dogs). All dogs were examined daily; bone healing was assessed via radiography and subjective lameness evaluation every 2 weeks. After euthanasia at 8 weeks, tibiae were evaluated biomechanically and histologically. RESULTS: Control dogs required antimicrobial treatment for pin-site-related complications more frequently than did rhBMP-2/ACS-treated dogs. At 4 and 6 weeks, weight bearing was greater in dogs treated with rhBMP-2/ACS (0.2 mg/mL) than in control dogs, albeit not significantly. Compared with control treatment, both doses of rhBMP-2/ACS accelerated osteotomy healing at 4, 6, and 8 weeks, and the 0.2 mg/mL dose enhanced healing at 2 weeks; healing at 6 weeks was greater for the lower-dose treatment than for the higher-dose treatment. Histologically, healing at 8 weeks was significantly improved for both rhBMP-2/ACS treatments, compared with control treatment. Among groups, biomechanical variables did not differ, although less osteotomy-site failures occurred in rhBMP-2/ACS-treated groups. CONCLUSIONS AND CLINICAL RELEVANCE: In dogs that underwent tibial osteotomy, rhBMP-2/ACS (0.2 mg/mL) appeared to accelerate bone healing and reduce lameness (compared with control treatment) and apparently augmented bone healing more than rhBMP-2/ACS (0.4 mg/mL). Compared with control dogs, rhBMP-2/ACS-treated dogs required antimicrobial treatments less frequently.
Chad W Schmiedt; Yan Lu; Kathleen Heaney; Peter Muir; Deborah M Amodie; Mark D Markel
Related Documents :
22228133 - Radiation doses to the population of the emilia-romagna region from medical exposures.
23294333 - A safety study on single intravenous dose of tetrachloro-diphenyl glycoluril [iodogen] ...
15725413 - Effects of 17beta-oestradiol on cerebral ischaemic damage and lipid peroxidation.
Publication Detail:
Type:  Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of veterinary research     Volume:  68     ISSN:  0002-9645     ISO Abbreviation:  Am. J. Vet. Res.     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-08-02     Completed Date:  2007-11-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375011     Medline TA:  Am J Vet Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  834-40     Citation Subset:  IM    
Comparative Orthopaedic Research Laboratory, Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706-1100, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Morphogenetic Proteins / administration & dosage*,  pharmacology*,  therapeutic use
Dose-Response Relationship, Drug
Fracture Healing / drug effects*
Fractures, Bone / drug therapy*
Recombinant Proteins
Surgical Sponges*
Reg. No./Substance:
0/Bone Morphogenetic Proteins; 0/Recombinant Proteins; 9007-34-5/Collagen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of treatment with polysulfated glycosaminoglycan on serum cartilage oligomeric matrix protei...
Next Document:  Subchondral bone density and cartilage degeneration patterns in osteoarthritic metacarpal condyles o...